CBD Legal Status: Federal Law, State Regulations & 2026 Updates

Executive Summary

CBD's legal status in the United States remains a complex patchwork of federal allowances and regulatory gaps, with the Trump administration now pushing Congress to codify protections for cannabidiol access amid ongoing enforcement uncertainty. The 2018 Farm Bill legalized hemp-derived CBD containing less than 0.3% THC at the federal level, removing it from Schedule I of the Controlled Substances Act. However, the Food and Drug Administration has maintained that CBD cannot be legally added to food or marketed as a dietary supplement without agency approval, creating a multibillion-dollar industry operating in regulatory limbo. As of June 2026, the administration's congressional push represents the first major federal effort to reconcile the FDA's enforcement posture with the widespread commercial reality of CBD products in gas stations, pharmacies, and online retailers nationwide. This legislative initiative comes as the CBD market approaches $10 billion in annual sales, with millions of Americans using cannabidiol products for pain, anxiety, sleep, and inflammation despite the absence of FDA-approved therapeutic claims for most applications.

Why CBD Legal Status Matters

The legal ambiguity surrounding CBD affects a $9.7 billion industry, approximately 64 million American consumers, thousands of farmers, and the regulatory framework governing cannabis policy nationwide. According to a 2025 Consumer Reports survey, one in four American adults has used a CBD product in the past year, with usage concentrated among adults over 50 seeking alternatives to prescription medications. The hemp farming sector supports approximately 94,000 jobs across 34 states, with CBD extraction and processing representing the primary revenue driver for most operations. The FDA's enforcement discretion has created a two-tier market. Large retailers including CVS, Walgreens, and Kroger stock CBD topicals and tinctures while carefully avoiding ingestible products or therapeutic claims. Meanwhile, thousands of smaller operators sell CBD edibles, beverages, and capsules with minimal regulatory oversight, creating consumer safety concerns and quality control inconsistencies. Laboratory testing by the FDA in 2024 found that 43% of CBD products contained significantly less cannabidiol than labeled, while 18% contained THC levels exceeding the 0.3% legal threshold. For medical patients, the legal uncertainty has real consequences. Veterans Affairs physicians cannot recommend CBD products despite patient demand, as VA policy prohibits discussion of non-FDA-approved cannabis therapies. Medicare and Medicaid do not cover CBD products, leaving elderly and disabled patients to pay out-of-pocket for products that may or may not contain advertised ingredients. The only FDA-approved CBD medication, Epidiolex for rare seizure disorders, costs approximately $32,500 annually, while unregulated CBD oils retail for $30-150 per bottle.

Background and History: From Schedule I to Regulatory Limbo

CBD's journey from prohibited substance to legal-but-unregulated commodity spans five decades of shifting federal policy, state experimentation, and agricultural advocacy.

The Controlled Substances Act Era (1970-2014)

The Controlled Substances Act of 1970, codified at 21 U.S.C. § 812, placed cannabis and all its derivatives in Schedule I, the most restrictive category reserved for substances with no accepted medical use and high abuse potential. This classification made no distinction between intoxicating THC and non-psychoactive CBD, effectively criminalizing all cannabinoids. For four decades, CBD research required DEA licensing, limiting scientific investigation to a handful of institutions. The first significant crack in this framework came in 2014 when Congress passed the Agricultural Act of 2014, which included Section 7606 authorizing state departments of agriculture and higher education institutions to grow industrial hemp for research purposes. This provision, championed by Senate Majority Leader Mitch McConnell of Kentucky, allowed pilot programs in states including Colorado, Kentucky, Oregon, and North Carolina. Between 2014 and 2018, hemp acreage under cultivation grew from 2,000 acres to approximately 78,000 acres nationwide.

The 2018 Farm Bill Breakthrough

On December 20, 2018, President Donald Trump signed the Agriculture Improvement Act of 2018 into law. Section 10113 of the legislation removed hemp—defined as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis—from the definition of marijuana in the Controlled Substances Act. This single provision legalized hemp cultivation, processing, and sale at the federal level, transferring regulatory authority from the DEA to the U.S. Department of Agriculture. The 0.3% threshold originated from a 1976 taxonomic paper by Canadian researchers Ernest Small and Arthur Cronquist, who acknowledged the distinction was arbitrary and chosen for practical classification purposes rather than pharmacological differences. Nevertheless, this figure became federal law, creating a bright-line rule that would govern the industry. The Farm Bill explicitly preserved FDA authority over CBD products, stating that nothing in the hemp provisions affected the agency's jurisdiction under the Federal Food, Drug, and Cosmetic Act. This preservation clause set up the regulatory conflict that persists today.

FDA Enforcement Position (2019-Present)

On May 31, 2019, the FDA held a public hearing on cannabis-derived products, receiving testimony from researchers, industry representatives, and consumer advocates. FDA Commissioner Scott Gottlieb testified before Congress that the agency could not allow CBD in food or dietary supplements because Epidiolex, approved in June 2018 for Dravet syndrome and Lennox-Gastaut syndrome, established CBD as an active pharmaceutical ingredient. Under 21 U.S.C. § 331(ll), substances investigated as new drugs cannot be added to food or sold as supplements, even if the drug approval came after the substance entered commerce. The FDA issued warning letters to 15 CBD companies in November 2019, citing violations including unsubstantiated health claims, mislabeling, and marketing CBD as dietary supplements. Between 2019 and 2025, the agency issued approximately 180 warning letters but conducted no criminal prosecutions and seized no products, signaling enforcement discretion focused on egregious violators making drug claims. In March 2023, the FDA released a consumer update acknowledging that the agency was evaluating potential regulatory pathways for CBD products but provided no timeline for action. This statement came after Congress directed the FDA in the 2022 appropriations bill to issue a report on CBD regulatory options within 180 days—a deadline the agency missed.

State-Level Legalization Wave (2019-2026)

As federal regulators debated, states moved forward. By January 2020, 47 states had enacted laws explicitly legalizing hemp-derived CBD, with Idaho, Nebraska, and South Dakota maintaining restrictions. South Dakota voters approved a hemp legalization measure in November 2020, which the legislature implemented in 2021. Nebraska followed in 2022, leaving Idaho as the sole state prohibiting hemp-derived CBD until the legislature passed the Idaho Hemp Act in March 2023. States adopted varying approaches to CBD regulation. California required CBD products to undergo testing for potency, pesticides, and heavy metals under the Medicinal and Adult-Use Cannabis Regulation and Safety Act. New York established a separate hemp program under the Department of Agriculture and Markets, creating a licensing system for CBD manufacturers and retailers. Texas initially prohibited CBD in food products, then reversed course in 2019 after the Farm Bill passage, with the Department of State Health Services issuing guidance that hemp-derived CBD was legal in consumable products.

Key Players in the CBD Legal Landscape

U.S. Food and Drug Administration

The FDA holds statutory authority over food, drugs, and dietary supplements, positioning the agency as the primary federal regulator determining CBD's legal status in consumer products. Under Commissioner Robert Califf, who returned to lead the agency in February 2022, the FDA has maintained that existing statutory frameworks prohibit CBD in food and supplements while acknowledging that enforcement resources focus on products making therapeutic claims or posing safety risks. The agency's Center for Food Safety and Applied Nutrition oversees CBD policy, while the Center for Drug Evaluation and Research approved Epidiolex and evaluates new drug applications for cannabinoid medications.

U.S. Department of Agriculture

The USDA's Agricultural Marketing Service administers the U.S. Domestic Hemp Production Program, established under the 2018 Farm Bill. The final rule, published October 31, 2019 and amended March 19, 2021, established requirements for hemp cultivation including sampling procedures, testing protocols, and disposal methods for non-compliant crops. The USDA has approved 73 state and tribal hemp plans as of May 2026, covering approximately 450,000 licensed acres. The agency does not regulate CBD extraction or product manufacturing, limiting its role to agricultural production.

Drug Enforcement Administration

The DEA lost primary jurisdiction over hemp-derived CBD through the 2018 Farm Bill but retains authority over synthetic cannabinoids and products exceeding 0.3% THC. The agency's Diversion Control Division issues registrations for cannabis research and maintains the federal marijuana supply contract with the University of Mississippi. In May 2024, the DEA published a Notice of Proposed Rulemaking to reschedule marijuana from Schedule I to Schedule III, but this action would not affect hemp-derived CBD's legal status, as hemp remains outside the Controlled Substances Act definition of marijuana.

Hemp Industry Association

Founded in 1994 and rebranded as the U.S. Hemp Roundtable in 2017, this trade association represents approximately 1,800 hemp businesses including farmers, processors, and retailers. The organization lobbied extensively for the 2018 Farm Bill provisions and has advocated for FDA regulatory clarity. Executive Director Jonathan Miller has testified before Congress multiple times, arguing that the FDA's inaction has created an unregulated market that harms consumers and legitimate businesses alike.

Charlotte's Web and Major CBD Brands

Charlotte's Web, named for Charlotte Figi, a child with Dravet syndrome whose seizures reportedly improved with CBD treatment, became the industry's flagship brand. The Stanley Brothers of Colorado developed the high-CBD, low-THC strain and built a vertically integrated company that went public on the Canadian Securities Exchange in 2018. The company reported $95 million in revenue in 2024, down from a peak of $186 million in 2020, reflecting market saturation and regulatory uncertainty. Other major brands including cbdMD, Medterra, and Lazarus Naturals have similarly called for federal regulatory frameworks to legitimize the industry and enable banking access.

Consumer Advocacy and Opposition Groups

Smart Approaches to Marijuana, led by Kevin Sabet, has opposed broad CBD legalization, arguing that insufficient research exists on long-term effects and that the unregulated market exposes consumers to unknown risks. The organization has called for FDA enforcement against CBD products making health claims and supported restrictions on CBD marketing to minors. Conversely, the Epilepsy Foundation and Americans for Safe Access have advocated for expanded CBD access, citing patient testimonials and the FDA's approval of Epidiolex as evidence of therapeutic potential.

Legal and Regulatory Framework

CBD's legal status derives from the intersection of the Controlled Substances Act, the Federal Food Drug and Cosmetic Act, the 2018 Farm Bill, and state-level hemp statutes, creating a complex regulatory matrix with no single controlling authority.

Federal Statutes

The Agricultural Improvement Act of 2018, Public Law 115-334, amended the Agricultural Marketing Act of 1946 to add Section 297A, defining hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition explicitly removed hemp from 21 U.S.C. § 802(16), the Controlled Substances Act's definition of marijuana. However, Section 12619 of the Farm Bill preserved FDA authority, stating: "Nothing in this section shall affect or modify the authority of the Secretary of Health and Human Services or the Commissioner of Food and Drugs under the Federal Food, Drug, and Cosmetic Act." This preservation clause, codified at 21 U.S.C. § 812 note, ensures that hemp-derived substances remain subject to FDA regulation as food, drugs, or dietary supplements. The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., prohibits introducing into interstate commerce any food containing an unapproved food additive or any dietary supplement containing an article authorized for investigation as a new drug for which substantial clinical investigations have been instituted and made public. The FDA interprets 21 U.S.C. § 331(ll), added by the Dietary Supplement Health and Education Act of 1994, as prohibiting CBD in supplements because clinical trials for Epidiolex were publicly disclosed before CBD was marketed as a supplement—a chronology disputed by industry advocates who note CBD products existed in commerce before Epidiolex trials began.

Case Law and Enforcement Actions

No federal court has issued a definitive ruling on CBD's status under the Food, Drug, and Cosmetic Act. The closest precedent came in Hemp Industries Association v. DEA, 333 F.3d 1082 (9th Cir. 2003), where the Ninth Circuit held that the DEA could not regulate naturally occurring THC in hemp products below the psychoactive threshold. While this case predated the 2018 Farm Bill and addressed THC rather than CBD, courts have cited it for the proposition that non-psychoactive hemp derivatives merit distinct treatment from marijuana. State-level litigation has produced mixed results. In Indiana, the state attorney general issued an opinion in 2018 that CBD remained illegal under state law despite the Farm Bill, prompting the legislature to pass Senate Enrolled Act 516 in 2019 explicitly legalizing hemp-derived CBD. In Texas, the Department of State Health Services initially prohibited CBD in food, leading to a lawsuit by the Texas Hemp Industries Association; the state reversed its position before trial. The most significant enforcement action came in United States v. Greenfield, where federal prosecutors in South Dakota charged a CBD retailer with marijuana distribution in 2020, before South Dakota legalized hemp. The case was dismissed after the state's hemp law took effect, but it demonstrated the potential for criminal liability in jurisdictions without explicit state-level protections.

Interstate Commerce and Banking

Hemp-derived CBD can legally cross state lines under the Farm Bill's commerce clause provisions, which prohibit states from banning the transportation of hemp through their territory. However, financial institutions remain cautious. The Bank Secrecy Act requires banks to file Suspicious Activity Reports for marijuana-related businesses, and many institutions cannot distinguish between hemp-derived CBD and marijuana-derived products in their compliance systems. The SAFE Banking Act, which would protect financial institutions serving cannabis businesses, has passed the House of Representatives seven times since 2019 but has not advanced in the Senate. CBD businesses frequently lose merchant processing accounts and struggle to secure business loans, operating largely in cash despite their products' federal legality.

State-by-State CBD Legal Status

All 50 states now permit hemp-derived CBD in some form, but regulatory approaches vary significantly in licensing requirements, testing standards, and retail restrictions.

California

California legalized hemp cultivation in 2016 and aligned its hemp definition with the federal 0.3% THC threshold in 2019. The California Department of Food and Agriculture administers the hemp program, requiring registration for cultivators and testing for cannabinoid content, heavy metals, pesticides, and microbial contaminants. The state initially prohibited CBD in food products pending FDA guidance, but Assembly Bill 228, effective January 1, 2022, explicitly authorized hemp-derived CBD in food and cosmetics. Possession limits do not apply to hemp-derived CBD, and the state allows online sales and interstate shipping.

New York

New York established its hemp program under Article 29 of the Agriculture and Markets Law in 2019. The Department of Agriculture and Markets licenses hemp processors and requires cannabinoid testing by ISO-accredited laboratories. New York permits CBD in food products and dietary supplements, with the Department of Health issuing guidance that CBD products cannot make therapeutic claims without FDA approval. The state prohibits CBD sales to individuals under 21 and requires retailers to register with the state. New York collected approximately $2.8 million in hemp licensing fees in fiscal year 2025.

Texas

Texas legalized hemp through House Bill 1325 in 2019, establishing the Texas Department of Agriculture as the regulatory authority. The state requires testing for total THC (delta-9 THC plus THCA multiplied by 0.877) rather than delta-9 THC alone, creating a more restrictive standard than federal law. Texas permits CBD in consumable products including food, beverages, and cosmetics. The state has approximately 3,200 licensed hemp growers and 890 licensed processors as of April 2026. Possession limits do not apply to hemp-derived CBD products.

Florida

Florida implemented its hemp program in 2019 under the Florida Department of Agriculture and Consumer Services. The state requires hemp processors to obtain a food permit and follow good manufacturing practices. Florida allows CBD in food products and dietary supplements, with the department issuing guidance that products cannot contain more than 0.3% total THC. The state prohibits smokable hemp flower, a restriction upheld by the Florida Supreme Court in 2022. Florida has issued approximately 1,800 hemp cultivation licenses and 450 processing licenses.

Colorado

Colorado pioneered hemp cultivation under the 2014 Farm Bill pilot program and transitioned to the USDA-approved state plan in 2020. The Colorado Department of Agriculture regulates hemp farming, while the Department of Public Health and Environment oversees CBD product manufacturing. Colorado requires testing for potency, pesticides, heavy metals, and residual solvents. The state allows CBD in food products and has established a voluntary certification program for CBD manufacturers meeting enhanced testing standards. Colorado's hemp industry generated approximately $425 million in revenue in 2024.

Idaho

Idaho was the last state to legalize hemp, passing the Idaho Hemp Act in March 2023 after years of resistance from law enforcement. The state requires hemp products to contain zero THC, a standard stricter than federal law and effectively prohibiting most full-spectrum CBD products. Idaho allows CBD isolate products but requires testing documentation proving zero THC content. The state has issued approximately 45 hemp cultivation licenses since program inception.

Market and Business Implications

The CBD industry reached $9.7 billion in U.S. sales in 2025, but regulatory uncertainty has constrained growth, limited institutional investment, and created a fragmented market with minimal quality controls. The CBD market peaked in 2020 at approximately $4.6 billion in sales, driven by consumer enthusiasm following the 2018 Farm Bill and widespread media coverage of potential health benefits. Growth slowed significantly in 2021-2023 as the novelty wore off and the FDA's enforcement posture remained unclear. Market research firm Brightfield Group projected 2026 sales of $10.3 billion, representing compound annual growth of just 8% compared to earlier projections of 30-40% annual growth.

Retail Distribution Channels

CBD products reached mainstream retail in 2019-2020, with CVS adding CBD topicals to 800 stores, Walgreens stocking CBD products in 1,500 locations, and Kroger introducing CBD products in 945 stores across 17 states. These retailers focused on topical products including creams, lotions, and balms, avoiding ingestible products due to FDA uncertainty. The retail expansion stalled in 2021 as major chains awaited regulatory clarity. Specialty CBD retailers, including franchises like Your CBD Store and Sunmed, expanded rapidly from 2018-2021, with approximately 4,200 dedicated CBD stores operating nationwide by 2022. Many of these retailers struggled with profitability as online competition intensified and consumer acquisition costs increased. An estimated 1,200 CBD retail locations closed between 2022 and 2025. Online sales represent approximately 55% of CBD purchases, with direct-to-consumer brands including Charlotte's Web, cbdMD, and Medterra capturing significant market share. Amazon prohibits CBD product listings, creating opportunities for specialized e-commerce platforms including CBDistillery and Lazarus Naturals. Online retailers face payment processing challenges, with many relying on alternative processors charging 5-8% transaction fees compared to 2-3% for traditional credit card processing.

Multi-State Operator Impact

Large cannabis multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries initially avoided the hemp-derived CBD market, focusing on higher-margin THC products in adult-use and medical marijuana programs. However, several MSOs launched CBD lines in 2023-2024 to establish brand presence in non-legal states and capture consumers seeking non-intoxicating products. Curaleaf acquired Select CBD in 2021 for $18.5 million, significantly below the $100+ million valuations some CBD brands commanded in 2019. The regulatory uncertainty has prevented CBD companies from accessing traditional capital markets. While Canadian cannabis companies trade on major exchanges, U.S. CBD companies remain largely private or trade on over-the-counter markets with limited liquidity. Charlotte's Web's market capitalization fell from approximately $1.8 billion in 2019 to $180 million in 2025, reflecting investor pessimism about regulatory resolution and market maturation.

Wholesale Pricing and Margin Compression

CBD isolate wholesale pricing collapsed from approximately $5,000 per kilogram in 2018 to $300-500 per kilogram in 2025, reflecting oversupply and commoditization. Full-spectrum CBD oil wholesale prices fell from $3,000-4,000 per liter to $600-1,000 per liter over the same period. This pricing pressure forced many hemp farmers to exit the market, with U.S. hemp cultivation acreage declining from a peak of 146,000 acres in 2019 to approximately 54,000 acres in 2025. Retail margins compressed as competition intensified. CBD tinctures that retailed for $80-120 per 30ml bottle in 2019 now sell for $30-50, with discount brands available for under $20. Retailers reported gross margins declining from 60-70% in 2019 to 35-45% in 2025, making profitability difficult without significant scale or vertical integration.

Testing and Quality Control Economics

Third-party laboratory testing costs $200-500 per batch for potency, pesticides, heavy metals, and microbial contaminants. Small manufacturers producing 50-100 units per batch face testing costs of $2-10 per unit, significantly impacting margins on products retailing for $30-50. Larger manufacturers producing thousands of units per batch reduce per-unit testing costs to under $0.50, creating economies of scale that favor consolidation. The lack of federal testing standards has created inconsistency across laboratories. A 2024 study published in the Journal of the American Medical Association tested 25 CBD products at three different laboratories and found cannabinoid content results varying by more than 20% across labs for the same products, reflecting differences in testing methodologies and equipment calibration.

What Experts Say About CBD Regulation

Regulatory experts, industry leaders, and consumer advocates largely agree that federal legislative action is necessary to resolve CBD's ambiguous legal status, though they differ on the appropriate regulatory framework. According to testimony before the House Energy and Commerce Committee in 2023, former FDA Commissioner Scott Gottlieb stated that the agency lacks resources to create a comprehensive CBD regulatory pathway without congressional direction. Gottlieb noted that the FDA would need to establish dosing guidelines, labeling requirements, and safety thresholds, requiring toxicology studies and clinical data that the agency cannot compel from industry without statutory authority. Jonathan Miller of the U.S. Hemp Roundtable has argued that Congress should amend the Federal Food, Drug, and Cosmetic Act to explicitly authorize CBD in dietary supplements and food products, similar to the pathway created for conventional foods derived from new plant varieties. Miller testified before the Senate Agriculture Committee in 2024 that the current regulatory vacuum harms consumers by preventing quality standards and harms legitimate businesses by enabling bad actors to operate without consequences. Consumer Reports' food safety director, Brian Ronholm, has called for FDA regulation of CBD products including mandatory testing, labeling requirements, and enforcement against products making unsubstantiated health claims. According to Consumer Reports' 2025 analysis, the organization found that consumers cannot reliably determine CBD product quality or safety without federal standards, and that the current market resembles the unregulated dietary supplement industry before the 1994 Dietary Supplement Health and Education Act. Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at the University of California San Diego, has stated that while preliminary research suggests CBD may have therapeutic applications for anxiety, inflammation, and pain, the evidence base remains limited. Grant noted in a 2025 interview that most CBD research has focused on epilepsy, and that claims about CBD's effectiveness for other conditions outpace the scientific evidence. He called for increased federal research funding to establish efficacy and safety profiles for various CBD applications. Kevin Sabet of Smart Approaches to Marijuana has argued that CBD should remain under FDA drug approval pathways rather than being treated as a dietary supplement or food ingredient. According to Sabet's testimony before Congress in 2024, the organization believes that insufficient long-term safety data exists to justify widespread CBD availability, particularly for vulnerable populations including pregnant women and children.

What's Next: Legislative and Regulatory Outlook

The Trump administration's June 2026 push for congressional action on CBD represents the first major federal legislative initiative since the 2018 Farm Bill, with potential pathways including standalone CBD legislation or inclusion in the 2028 Farm Bill reauthorization. Congressional sources indicate that the administration is working with Senate Agriculture Committee leadership to draft legislation that would explicitly authorize CBD in dietary supplements and food products while establishing FDA oversight for labeling, testing, and good manufacturing practices. The proposed framework would reportedly create a notification system requiring CBD manufacturers to register with the FDA and submit testing data, similar to the New Dietary Ingredient notification process established under the Dietary Supplement Health and Education Act. The legislative calendar presents several opportunities for action. The Senate Agriculture Committee is scheduled to hold hearings on hemp and CBD regulation in July 2026, with testimony expected from FDA officials, USDA representatives, industry stakeholders, and consumer advocates. The House Energy and Commerce Committee's health subcommittee has scheduled a markup session for September 2026 to consider CBD legislation, though the specific bill text has not been released. The 2028 Farm Bill reauthorization represents a natural vehicle for CBD provisions, as the legislation must address hemp program reauthorization and could include comprehensive CBD regulatory language. However, waiting until 2028 would extend the current regulatory uncertainty for another two years, potentially leading to further market consolidation and continued consumer confusion.

Regulatory Scenarios

If Congress passes standalone CBD legislation in 2026-2027, the FDA would likely require 18-24 months to promulgate implementing regulations, establish testing standards, and create an enforcement framework. Industry observers expect the agency would adopt a phased approach, initially focusing on registration and labeling requirements before implementing more stringent good manufacturing practice standards. If Congress takes no action, the FDA could theoretically issue guidance or regulations under existing statutory authority, but agency officials have consistently stated that congressional direction is necessary to resolve the fundamental conflict between the Farm Bill's hemp legalization and the Food, Drug, and Cosmetic Act's drug exclusion provision. Without legislative action, the current enforcement discretion approach would likely continue, leaving the industry in regulatory limbo. A third scenario involves state-level action filling the federal void. Several states including California, New York, and Colorado have established comprehensive CBD regulatory frameworks that could serve as models for federal legislation. However, a state-by-state approach creates interstate commerce complications and prevents national brands from achieving economies of scale in compliance and testing.

Key Decision Points and Timeline

• July 2026: Senate Agriculture Committee hearings on CBD regulation
• September 2026: House Energy and Commerce Committee markup of CBD legislation
• November 2026: Potential inclusion of CBD provisions in year-end omnibus appropriations legislation
• March 2027: USDA hemp program reauthorization deadline, requiring congressional action
• September 2027: FDA user fee reauthorization, potential vehicle for CBD provisions
• 2028: Farm Bill reauthorization process begins, comprehensive hemp and CBD review

The administration's involvement represents a significant shift from the previous hands-off approach to CBD regulation. Industry advocates view the congressional push as the strongest signal yet that federal legislative action is imminent, though the timeline remains uncertain given competing congressional priorities including appropriations, tax policy, and healthcare legislation.

Further Reading and Primary Sources

• Agricultural Improvement Act of 2018, Public Law 115-334, full text available at https://www.congress.gov/bill/115th-congress/house-bill/2
• U.S. Food and Drug Administration, "What You Need to Know About Cannabis Products," consumer update available at https://www.fda.gov/consumers/consumer-updates/what-you-need-know-about-cannabis-products
• U.S. Department of Agriculture, "U.S. Domestic Hemp Production Program," regulations and state plan approvals at https://www.ams.usda.gov/rules-regulations/hemp
• Drug Enforcement Administration, "Drug Scheduling," Controlled Substances Act schedules at https://www.dea.gov/drug-scheduling
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., available at https://uscode.house.gov/view.xhtml?path=/prelim@title21/chapter9&edition=prelim
• Hemp Industries Association v. DEA, 333 F.3d 1082 (9th Cir. 2003), full opinion at https://caselaw.findlaw.com/court/us-9th-circuit/1192383.html
• U.S. Hemp Roundtable, industry data and advocacy resources at https://www.hempsupporter.com
• Consumer Reports, "CBD Products Are Everywhere, But Do They Work?" testing results and analysis at https://www.consumerreports.org/cbd/cbd-products-are-everywhere-but-do-they-work/
• National Conference of State Legislatures, "State Industrial Hemp Statutes," comprehensive state law compilation at https://www.ncsl.org/agriculture-and-rural-development/state-industrial-hemp-statutes
• Congressional Research Service, "The 2018 Farm Bill: Hemp Cultivation and the Federal-State Regulatory Framework," report R46186 at https://crsreports.congress.gov